Latest Breaking News On - Tissue specific therapeutics - Page 6 : comparemela.com

Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson

Dr. Coleman joins the Nexcella, Inc. Board of Directors with over a decade of experience as an Independent Director of Johnson & Johnson from 2003-2016Dr. Coleman is President Emerita of

United statesUnited kingdomMichigan state universityIlya rachmanGary lockeGabriel morrisMary sue colemanLos angelesSuzanne messereJohns and jamesl knight foundationBoard of trustees society for scienceExchange commissionCancer centerImmix biopharma incCollege presidentsNotre dame university

Immix Biopharma (IMMX) Completes $5M At-The-Market Program

Immix Biopharma (IMMX) Completes $5M At-The-Market Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Suzanne messereIlya rachmanExchange commissionImmix biopharma incNexcella incImmix biopharmaChief executive officerTissue specific therapeuticsOrphan drug designationRare pediatric disease designationRisk factorAnnual report

Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program

LOS ANGELES, June 14, 2023 Immix Biopharma, Inc., , a biopharmaceutical company pioneering CAR-T cell therapies and tissue specific therapeutics targeting oncology and immuno-dysregulated. | June 14, 2023

Ilya rachmanSuzanne messereGlobenewswire incImmix biopharma incExchange commissionNexcella incCompany contactChief executive officerTissue specific therapeuticsOrphan drug designationRare pediatric disease designationRisk factorImmix biopharmaAnnual report

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr , former Chairman and CEO of Pfizer Inc , to Board of Directors

LOS ANGELES - Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. , today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc.,. | June 13, 2023

United kingdomAmerica phHenrya mckinnell jrSuzanne messereGabriel morrisIlya rachmanLos angelesOptimer pharmaceuticalsImmix biopharma inc nasdaqInternational advisory boardNexcella incExchange commissionUniversity of british columbiaCubist pharmaceuticalsThomash lee private equity partnershipCompany board of directors

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr , former Chairman & CEO of Pfizer Inc , to Board of Directors

Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive OfficerDr. McKinnell is a former. | June 12, 2023

United kingdomLos angelesSuzanne messereAmerica phIlya rachmanGabriel morrisHenrya mckinnell jrImmix biopharma inc nasdaqOptimer pharmaceuticalsNexcella incMoody corporationCubist pharmaceuticalsThomash lee private equity partnershipImmix biopharma incUniversity of british columbiaStanford university graduate school of business